PT-141: Melanocortin Agonism and MC4R signalling research
Research Focus: Unlike phosphodiesterase inhibitors, PT-141 (Bremelanotide) acts via the central nervous system. This post reviews its activation of MC3 and MC4 receptors to treat hypoactive sexual desire disorder (HSDD) in both clinical and research settings.
